Loading company…
Riskpilot
← Back to search
Sign in
Get full access
ZYMBIO AS
AS
Active
Org 978677266
Murbræk, 7760 Snåsa
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 1997
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 0
EBITDA margin
—
+11% vs 2023
Equity ratio
42.4%
Financial strength
Net profit 2024
NOK 149K
+563% vs 2023
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2020
0M
0%
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
NOK 0
—
EBITDA
NOK -31K
+11%
Net profit
NOK 149K
+563%
Total assets
NOK 2,4M
+7%
Equity
NOK 1M
+17%
Employees
0
—
Company information
Legal name
ZYMBIO AS
Org number
978677266
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. juli 1997
Share capital
NOK 183 660
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Contact
Address
Murbræk, 7760 Snåsa
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Snåsa
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
0M
2023
0M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
0M
2023
0M
2024
Income statement
NOK thousands
Item
2020
2021
2022
2023
2024
Revenue
16
0
0
0
0
Staff expenses
−0
−0
−0
−0
−0
EBITDA
−33
−21
−50
−35
−31
Depreciation & amort.
−15
−15
−15
−1
−0
EBIT
−49
−36
−66
−36
−31
Net financials
4
4
0
4
−11
Profit before tax
−44
−32
−66
−32
−42
Tax
−0
−0
−0
−0
−191
Net profit
−44
−32
−66
−32
149
Balance sheet
NOK thousands
Item
2020
2021
2022
2023
2024
Total assets
2 382
2 370
2 307
2 278
2 427
Equity
1 010
978
913
881
1 030
Long-term debt
0
0
0
0
0
Short-term debt
1 372
1 392
1 394
1 397
1 397
Total debt
1 372
1 392
1 394
1 397
1 397
Financial ratios
5-year trend
EBITDA margin
-3084900.0%
This company
15.8%
Market median
-19524784% vs market
2020
2024
Equity ratio
42.4%
This company
38.2%
Market median
+11% vs market
2020
2024
Return on equity
14.5%
This company
18.4%
Market median
+21% vs market
2020
2024
Net profit margin
14894900.0%
This company
8.1%
Market median
+183887554% vs market
2020
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2020
2024
Debt / equity
1.36×
This company
0.62×
Market median
-119% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
MB
Maria Brønstad
Deputy Member
Deputy Member
2009
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
GO
Gunnar Otto Brønstad
Chairman
2009
AB
Aase Brønstad
Board of Directors
2009
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Neurozym Biotech As
Company
100%
100%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Neurozym Biotech As
ZYMBIO AS
(this company)
Board network connections
Board members of ZYMBIO AS also hold positions in
0
other companies.
Person
Role here
Other companies
Maria Brønstad
Deputy Member
0 companies
Gunnar Otto Brønstad
Chairman
0 companies
Aase Brønstad
Board of Directors
0 companies